Clinical Trial Update: Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention [Phase 3]

View source ↗

Summary

Phase 3 trial of Aggrastat (tirofiban) in patients undergoing percutaneous coronary intervention for myocardial infarction or acute coronary syndrome has been w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Unstable Angina

Drugs mentioned

• Aggrastat (tirofiban)

Snippet

Sponsor: Medicure | Conditions: Myocardial Infarction, Acute Coronary Syndromes | Phase 3 | Status: WITHDRAWN